| 15.01 -0.18 (-1.18%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.52 | 1-year : | 21.63 |
| Resists | First : | 15.85 | Second : | 18.52 |
| Pivot price | 14.11  |
|||
| Supports | First : | 13.92 | Second : | 12.72 |
| MAs | MA(5) : | 14.56 |
MA(20) : | 14.18 |
| MA(100) : | 12.52 |
MA(250) : | 8.88 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 61.2 |
| RSI | RSI(14): 59  |
|||
| 52-week | High : | 15.85 | Low : | 4.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CMPS ] has closed below upper band by 18.5%. Bollinger Bands are 14.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.57 - 15.66 | 15.66 - 15.74 |
| Low: | 14.68 - 14.77 | 14.77 - 14.86 |
| Close: | 14.87 - 15.03 | 15.03 - 15.16 |
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Tue, 22 Sep 2026
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears - Yahoo Finance
Fri, 18 Sep 2026
COMPASS Pathways Plc (CMPS) Stock Analysis: Strong Buy Ratings and 58% Upside Potential - DirectorsTalk Interviews
Thu, 17 Sep 2026
COMPASS Pathways (CMPS) Quarterly Results: Clinical Pipeline Risk, Cash Runway Outlook, and Key Investor Watchpoints - AlphaStreet
Wed, 16 Sep 2026
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 - Yahoo Finance
Wed, 16 Sep 2026
COMPASS Pathways (CMPS) Stock May Be Fully Priced On Phase 3 Data - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 68.1 (%) |
| Shares Short | 14,100 (K) |
| Shares Short P.Month | 12,840 (K) |
| EPS | -3.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.1 % |
| Return on Equity (ttm) | -319.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -161 (M) |
| Levered Free Cash Flow | 250 (M) |
| PE Ratio | -3.97 |
| PEG Ratio | 0 |
| Price to Book value | 24.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|